The biotech sector has long offered investors high-risk, high-reward stocks. While large players are making headlines, the ...

Dyne Therapeutics’ stock sees record rally, but one analyst says it could still climb a lot further, after a rival got bought ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands ...

The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic. Click here for ...

Biotech stocks rebound after years of weakness as M&A, lower rates and easing policy fears draw investors back to the sector.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

On July 8, Jared Holz, Mizuho, joined ‘Closing Bell Overtime’ on CNBC to discuss if the biotech sector is ready for a breakout. Jared Holz admitted that the biotech sector has been exceptionally ...

In the past week or so, a fintech firm and two biotechs saw some huge insider buying. However, these were not the only ...

Realty Income's business strategy is clear, straightforward, and it works. It is founded on long-term leases focused on what ...

In the past week or so, a gold and silver miner, a struggling offshore driller, and a biotech saw some huge insider buying.